
    
      This trial is a prospective, single-centre, randomized controlled, and non-inferiority study
      in which all men suspicious to have clinically significant prostate cancer. This study aims
      to determine whether a novel three-dimensional matrix positioning cognitive fusion targeted
      biopsy is non-inferior to software-based fusion targeted biopsy in the detection rate of
      clinically significant cancer in men without a prior biopsy.
    
  